CA2378473A1 - Modulation de l'activation plaquettaire - Google Patents
Modulation de l'activation plaquettaire Download PDFInfo
- Publication number
- CA2378473A1 CA2378473A1 CA002378473A CA2378473A CA2378473A1 CA 2378473 A1 CA2378473 A1 CA 2378473A1 CA 002378473 A CA002378473 A CA 002378473A CA 2378473 A CA2378473 A CA 2378473A CA 2378473 A1 CA2378473 A1 CA 2378473A1
- Authority
- CA
- Canada
- Prior art keywords
- par4
- par1
- activity
- compound
- thrombin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des méthodes de modulation de l'activation plaquettaire induite par la thrombine par inhibition ou stimulation de l'activité des récepteurs PAR4 et PAR1 activés par des protéases. Cette méthode permet de bloquer sensiblement toute l'activation plaquettaire induite par la thrombine grâce à (1) l'inhibition de la signalisation par PAR1 et (2) l'inhibition de la signalisation par PAR4. La signalisation par chaque récepteur PAR peut être inhibée à différents niveaux moléculaires, tels que le niveau de liaison des ligands (par exemple lors de l'administration d'un antagoniste), le niveau d'activité d'un récepteur (par exemple lors du blocage de l'expression de ce récepteur dans les cellules appropriées) et/ou le niveau intracellulaire (par exemple lors du blocage de l'expression ou de l'activité d'une molécule nécessaire à l'activité dudit récepteur). Dans un autre mode de réalisation, cette méthode permet de stimuler l'activation plaquettaire induite par la thrombine par activation spécifique de PAR1 et PAR4. Ces méthodes peuvent s'appliquer in vivo, par administration des composés appropriés, ou in vitro, par exemple lors du traitement ex vivo d'un échantillon.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36048299A | 1999-07-23 | 1999-07-23 | |
US09/360,482 | 1999-07-23 | ||
PCT/US1999/019158 WO2001007072A1 (fr) | 1999-07-23 | 1999-08-24 | Modulation de l'activation plaquettaire |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2378473A1 true CA2378473A1 (fr) | 2001-02-01 |
Family
ID=23418153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002378473A Abandoned CA2378473A1 (fr) | 1999-07-23 | 1999-08-24 | Modulation de l'activation plaquettaire |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2003526625A (fr) |
CA (1) | CA2378473A1 (fr) |
WO (1) | WO2001007072A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060401A1 (fr) * | 2000-02-17 | 2001-08-23 | The Regents Of The University Of California | Methodes de modulation de l'activation du recepteur 4 active par des proteases (par4) avec de la cathepsine g |
JP5089388B2 (ja) | 2004-09-01 | 2012-12-05 | アラーガン、インコーポレイテッド | 分解可能なクロストリジウム毒素 |
GB2424833B (en) * | 2005-04-08 | 2008-12-10 | Nicholas John Larkins | Anti-inflammatory formulation comprising apocyanin and paeonol |
US7888483B2 (en) | 2006-07-18 | 2011-02-15 | Irm Llc | Antagonists of protease activated receptor-1 (PAR1) |
BRPI0813833A2 (pt) * | 2007-07-17 | 2015-01-06 | Irm Llc | Anticorpos antagonistas de receptor-1 ativado por protease (par1) |
GB201121513D0 (en) | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
US9518128B2 (en) | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
KR20240023705A (ko) * | 2013-06-28 | 2024-02-22 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
EP3060233A4 (fr) * | 2013-10-25 | 2017-04-12 | Bristol-Myers Squibb Company | Méthodes de diagnostic pour thérapie par antagonistes de par4 |
PT3091997T (pt) | 2014-01-10 | 2022-09-29 | Bioverativ Therapeutics Inc | Proteínas quiméricas de fator viii e utilizações destas |
WO2019030706A1 (fr) | 2017-08-10 | 2019-02-14 | Janssen Pharmaceutica Nv | Molécules d'anticorps anti-thrombine et méthodes d'utilisation en chirurgie orthopédique |
WO2019035055A1 (fr) | 2017-08-16 | 2019-02-21 | Janssen Pharmaceutica Nv | Molécules d'anticorps anti-thrombine et procédés d'utilisation avec des agents antiagrégants plaquettaires |
US11780915B2 (en) * | 2017-09-11 | 2023-10-10 | Monash University | Binding proteins to the human thrombin receptor, PAR4 |
SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
-
1999
- 1999-08-24 JP JP2001511955A patent/JP2003526625A/ja not_active Withdrawn
- 1999-08-24 WO PCT/US1999/019158 patent/WO2001007072A1/fr active Application Filing
- 1999-08-24 CA CA002378473A patent/CA2378473A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2003526625A (ja) | 2003-09-09 |
WO2001007072A1 (fr) | 2001-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6037324A (en) | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor | |
US8354378B2 (en) | G protein coupled receptor antagonists and methods of activating and inhibiting G protein coupled receptors using the same | |
US5837809A (en) | Mammalian opioid receptor ligand and uses | |
JP5554696B2 (ja) | 組換え血小板コラーゲン受容体糖タンパク質viおよびその薬学的使用 | |
Schraw et al. | A role for Sec1/Munc18 proteins in platelet exocytosis | |
CA2378473A1 (fr) | Modulation de l'activation plaquettaire | |
JP2003159088A (ja) | 組換えトロンビンレセプターおよびそれに関連した薬剤 | |
Palm et al. | Identification of a Gs‐protein coupling domain to the β‐aderenoceptor using site‐specific synthetic peptides: Carboxyl terminus of Gsα is involved in coupling to β‐adrenoceptors | |
US5614370A (en) | Assay to identify human C5a antagonists and agonists | |
US5892014A (en) | DNA encoding a protease-activated receptor 3 | |
JP2002504369A (ja) | プロテアーゼ活性化レセプター4およびその使用。 | |
EP0920630B1 (fr) | Proteines de liaison au prion et leur utilisation | |
WO1989004834A1 (fr) | Agent concurrent de l'immunoglobuline e | |
FI112801B (fi) | Menetelmä ja välineitä kollageenin indusoiman verihiutaleaggregaation inhibiittorin tuottamiseksi | |
US5693758A (en) | Immunoglobulin E competitor | |
WO2001000235A1 (fr) | Proteines de liaison a la proteine prion, et leurs utilisations | |
Cheng et al. | An inhibitor selective for collagen-stimulated platelet aggregation from the salivary glands of hard tick Haemaphysalis longicornis and its mechanism of action | |
WO2002057313A2 (fr) | Composes de liaison et procedes d'identification de ces derniers | |
US20030167129A1 (en) | Binding compounds and methods for identifying binding compounds | |
Maurice et al. | Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse | |
CA2067766A1 (fr) | Recepteur peptidique liberant de la gastrine | |
CA2404139A1 (fr) | Composes de fixation et procede d'identification de composes de fixation | |
CA2637006A1 (fr) | Inhibiteurs specifiques des trpm2 | |
Barnard et al. | Opioid receptors | |
Monboisse et al. | The Interaction of Human Neutrophils with Type IV Collagen Involves an Inhibitory Signal Transduction Pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |